Prosecution Insights
Last updated: April 19, 2026

Aurigene Discovery Technologies Limited

6 pending office actions

Portfolio Summary

6
Total Pending OAs
3
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19198975 COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE HIBSHMAN, SARAH GRACE 1693 Final Rejection May 05, 2025
18406841 Method for Treating Diseases Using SMARCA2/4 Degraders JACKSON, SHAWQUIA 1626 Non-Final OA Jan 08, 2024
18564384 CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT ROMERO, KRISTEN WANG 1624 Non-Final OA Nov 27, 2023
18257962 COCRYSTAL OF A CDK INHIBITOR LEE, CHIHYI NMN 1628 Non-Final OA Jun 16, 2023
18044329 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS MOORE, SUSANNA 1624 Final Rejection Mar 07, 2023
17045916 METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS VALENROD, YEVGENY 1628 Final Rejection Oct 07, 2020

Managing Aurigene Discovery Technologies Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month